1. Home
  2. ADAP vs AMTD Comparison

ADAP vs AMTD Comparison

Compare ADAP & AMTD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ADAP
  • AMTD
  • Stock Information
  • Founded
  • ADAP 2008
  • AMTD 2003
  • Country
  • ADAP United Kingdom
  • AMTD France
  • Employees
  • ADAP N/A
  • AMTD N/A
  • Industry
  • ADAP Biotechnology: Pharmaceutical Preparations
  • AMTD
  • Sector
  • ADAP Health Care
  • AMTD
  • Exchange
  • ADAP Nasdaq
  • AMTD Nasdaq
  • Market Cap
  • ADAP 75.5M
  • AMTD 80.2M
  • IPO Year
  • ADAP 2015
  • AMTD 2019
  • Fundamental
  • Price
  • ADAP $0.25
  • AMTD $1.03
  • Analyst Decision
  • ADAP Buy
  • AMTD
  • Analyst Count
  • ADAP 6
  • AMTD 0
  • Target Price
  • ADAP $1.52
  • AMTD N/A
  • AVG Volume (30 Days)
  • ADAP 595.5K
  • AMTD 71.5K
  • Earning Date
  • ADAP 08-11-2025
  • AMTD 07-01-2025
  • Dividend Yield
  • ADAP N/A
  • AMTD N/A
  • EPS Growth
  • ADAP N/A
  • AMTD N/A
  • EPS
  • ADAP N/A
  • AMTD 0.76
  • Revenue
  • ADAP $179,639,000.00
  • AMTD $67,032,000.00
  • Revenue This Year
  • ADAP N/A
  • AMTD N/A
  • Revenue Next Year
  • ADAP $35.48
  • AMTD N/A
  • P/E Ratio
  • ADAP N/A
  • AMTD $1.35
  • Revenue Growth
  • ADAP 878.53
  • AMTD N/A
  • 52 Week Low
  • ADAP $0.20
  • AMTD $0.92
  • 52 Week High
  • ADAP $1.48
  • AMTD $1.79
  • Technical
  • Relative Strength Index (RSI)
  • ADAP 42.09
  • AMTD 45.59
  • Support Level
  • ADAP $0.24
  • AMTD $0.93
  • Resistance Level
  • ADAP $0.27
  • AMTD $1.01
  • Average True Range (ATR)
  • ADAP 0.02
  • AMTD 0.07
  • MACD
  • ADAP -0.00
  • AMTD -0.01
  • Stochastic Oscillator
  • ADAP 23.57
  • AMTD 21.11

About ADAP Adaptimmune Therapeutics plc

Adaptimmune Therapeutics PLC is a commercial-stage biopharmaceutical company working to redefine the treatment of solid tumor cancers with cell therapies. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A4 SPEAR T-cell therapy, NY-ESO SPEAR T-cell, CD70, and others for multiple cancer types.

About AMTD AMTD IDEA Group each representing six (6)

AMTD IDEA Group is a financial institution operating in five business segments: The capital market solutions segment assists customers in raising funds through equity and debt financing, private placements, and debt issuances. The digital solutions and other services segment provides institutional and corporate clients with paid access to enhance investor communication and relations, corporate communication also provides digital financial solution services. The Media and entertainment segment offers print and digital advertising campaigns, licensing, and marketing services including branded content, video production. The hotel operations, hospitality, and VIP services segment engages in hotel investments, hotel operations, hospitality, and VIP services; and Strategic investment segment.

Share on Social Networks: